Abstract: Provided is a method for modifying a chimeric antigen receptor-modified T cell (CAR-T cell). The method comprises expressing an SCFV-CDS TM-4-1BB-CD3? molecule in a T cell. The CAR-T cell prepared using the method can specifically recognize and bind to a tumor cell with elevated expression of a ROBO1 protein, and can be used to prevent and treat a corresponding tumor-related disease.

Abstract: The present disclosure relates to the field of display technology, and provides a light guiding film. The light guiding film includes a plurality of prism bodies arranged as an array. Each of the plurality of prism bodies has a first surface and a second surface oppositely disposed. The first surface is a light exiting surface. A space is disposed between two adjacent prism bodies. The prism body is configured to refract light incident into the space to form refracted light, such that the refracted light is totally reflected in the prism body to form total reflection light.

Abstract: An anti-CD47 monoclonal antibody and use thereof. The provided anti-CD47 monoclonal antibody can effectively inhibit tumor growth. Blocking human SIRP and human CD47 signals may enhance macrophage phagocytosis of tumor cells, prevent the tumor cells from escaping a tumor immune defense system, and have an anti-tumor function. Blocking association between the CD47 on a tumor cell surface and the SIRP on a macrophage surface may block a “do not eat me” signal from the tumor cells, promoting tumor cell recognition and uptake of macrophages, and thereby facilitating tumor cells to be phagocytosed. The association between the CD47 on a tumor cell surface and the SIRP on a macrophage surface is a common “do not eat me” signal. The anti-CD47 antibody, as a very promising target in the tumor immune system, will play a powerful and effective role in human cancer therapy.

Abstract: The present disclosure relates to a light guide plate and its fabricating method, as well as a backlight module. The light guide plate comprises a light-transmitting plate body provided with a plurality of light guide dots on a light-exiting surface thereof, and further provided with a plurality of dimming pits, wherein a plurality of light guide dots are provided around each of the dimming pits; an inner wall of each of the dimming pits sequentially includes multiple levels of dimming surfaces along a depth direction of the dimming pits, for reflecting light incident thereon to the light guide dots. The backlight module comprises the light guide plate provided in the above-described technical solution.

Abstract: The present invention belongs to the field of tumor therapy and molecular immunology, and relates to a PDL-1 antibody, a pharmaceutical composition thereof and use thereof. In particular, the present invention relates to a PDL-1 monoclonal antibody or an antigen-binding fragment thereof, wherein the monoclonal antibody has a heavy chain variable region comprising CDRs as set forth in SEQ ID NOs: 15-17; and/or has a light chain variable region comprising CDRs as set forth in SEQ ID NOs: 18-20. The monoclonal antibody of the present invention can bind to PDL-1 specifically, and specifically remove immunosuppressive function of PDL-1 and activate T lymphocytes.

Abstract: The present invention discloses an electric connector plug, an electric connector socket and an electric connector assembly, which are applied to the butting of connector for a power supply, and capable of avoiding the generation of spark in butting and reducing supply temperature in butting. The electric connector plug, electric connector socket, and electric connector assembly are functional in non-directional butting and can supply large current to electronic apparatuses.

Abstract: A memory structure provided by this invention includes a first substrate, a dielectric layer, a bonding pad, and an isolation structure. The first substrate includes a substrate layer and a memory layer. The substrate layer has opposite first and second surfaces, the memory layer is located on the first surface of the substrate layer, and the first substrate includes a bonding pad region. The dielectric layer is disposed on the second surface of the substrate layer. The bonding pad is disposed on the surface of the dielectric layer in the bonding pad region. The isolation structure penetrates through the substrate layer and is disposed at the edge of the bonding pad region and surrounds the substrate layer in the bonding pad region, and the isolation structure is used for isolating the substrate layer in the bonding pad region from the substrate layer at the periphery of the isolation structure.

Abstract: Disclosed are a stabilizer for storage of a biological sample, a composition for storage of a nucleic acid and/or a polypeptide in a biological sample under non-freezing conditions, a kit comprising the composition, a mixture comprising the composition and a biological sample, and a method for storage of a nucleic acid and/or a polypeptide in a biological sample under non-freezing conditions. The integrity and stability of the nucleic acid and/or polypeptide in a biological sample can be stored for a long time under non-freezing conditions by using the stabilizer according to the invention, and therefore the stabilizer has a good application prospect.

Abstract: The present invention belongs to the field of tumor therapy and molecular immunology, and relates to a PDL-1 antibody, a pharmaceutical composition thereof and use thereof. In particular, the present invention relates to a PDL-1 monoclonal antibody or an antigen-binding fragment thereof, wherein the monoclonal antibody has a heavy chain variable region comprising CDRs as set forth in SEQ ID NOs: 15-17; and/or has a light chain variable region comprising CDRs as set forth in SEQ ID NOs: 18-20. The monoclonal antibody of the present invention can bind to PDL-1 specifically, and specifically remove immunosuppressive function of PDL-1 and activate T lymphocytes.

Abstract: The present disclosure relates to the field of display technology, and provides a light guiding film. The light guiding film includes a plurality of prism bodies arranged as an array. Each of the plurality of prism bodies has a first surface and a second surface oppositely disposed. The first surface is a light exiting surface. A space is disposed between two adjacent prism bodies. The prism body is configured to refract light incident into the space to form refracted light, such that the refracted light is totally reflected in the prism body to form total reflection light.

Abstract: Provided are Christensenella intestinihominis and an application thereof, specifically, use of Christensenella intestinihominis in treating and preventing obesity and related diseases thereof. Also provided are a composition for treating and preventing obesity and related diseases thereof, comprising compositions of drugs, drinks, food, or animal feed, and a method for reducing weight and/or blood lipid.

Abstract: A method for erasing a memory cell includes applying a first erase to memory cells to erase the memory cells, wherein first memory cells are in a weakly erased state in response to the first erase, and wherein second memory cells are in a normally erased state in response to the first erase, thereafter applying a first weak program to the memory cells, wherein the second memory cells enter a programmed state and the third memory cells remain in the erased state in response to the first weak program, and thereafter applying a read to the memory cells to identify the second memory cells, and applying a second erase to the second memory cells to thereby erase the second memory cells.

Abstract: Provided are a biologically pure Faecalibacterium butyricigenerans strain AF52-21 deposited under CGMCC Accession No. 1.5206 and a composition including the same and a carrier. A method for treating an inflammation-related disease in a subject in need thereof is also provided.

Abstract: Provided are Faecalibacterium longum and an application thereof, specifically, use of Faecalibacterium longum in treating and preventing diabetes and related diseases thereof. Also provided are a composition for treating and preventing diabetes and related diseases thereof, comprising compositions of drugs, drinks, food, or animal feed, and a method for reducing weight, fasting plasma glucose and/or blood lipid, and improving glucose tolerance.

Abstract: The present invention discloses a fiducial node DC voltage based DC voltage droop control method with dead-band for HVDC grids. Two levels of DC voltage control e.g. primary and secondary DC voltage regulation are introduced to realize load sharing and DC voltage control in HVDC grids. In the process of primary DC voltage regulation, the power flow regulation ability of the entire HVDC grids can be significantly improved, and the DC voltage and stability of the HVDC grids will be quickly controlled and guaranteed for the benefit of droop characteristic. Secondary DC voltage regulation is achieved by by introducing the load-DC voltage controller. In the process of secondary DC voltage regulation, the burden of accommodating power imbalance by the DC voltage fiducial node will be alleviated, thus improving the ability to resist disturbances of the entire HVDC grids.

Abstract: The present invention provides an anti-ErbB2 antibody-drug conjugate, a composition comprising the conjugate, a method for preparing the conjugate, use of the conjugate.

Abstract: Disclosed are a stabilizer for storage of a biological sample, a composition for storage of a nucleic acid and/or a polypeptide in a biological sample under non-freezing conditions, a kit comprising the composition, a mixture comprising the composition and a biological sample, and a method for storage of a nucleic acid and/or a polypeptide in a biological sample under non-freezing conditions. The integrity and stability of the nucleic acid and/or polypeptide in a biological sample can be stored for a long time under non-freezing conditions by using the stabilizer according to the invention, and therefore the stabilizer has a good application prospect.

Abstract: An efficient LED intelligent light source, comprising an encapsulation substrate and a chip unit arranged on the encapsulation substrate, wherein the chip unit comprises at least one bare chip unit and at least one wrapped chip unit formed by covering the surface of the bare chip unit with a layer of first fluorescent layer (a); colour temperatures of the bare chip unit and the wrapped chip unit are different; and a second fluorescent layer is further arranged to cover the bare chip unit and the wrapped chip unit. The efficient LED intelligent light source has good light-colour consistency and is even in light, and the light-colour continuity after colour mixing is enhanced, thereby avoiding the layering phenomenon of a light-mixed partition. An integrally encapsulated LED light source has good air tightness, high reliability and high light-colour quality and is convenient to manufacture.